美国 · 交易所与实时行情 · Nasdaq
BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate
(RTTNews) - On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3…
在 Nasdaq 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.nasdaq.com)
